Furthermore, HTRA1 was discovered, with an additional 2 genes, MTSS1 and CLPTM1, to be an indicator of doxorubicin-sensitive disease among nonresponsive BC cases in 95% of samples [55]. This evidence concerns the gene HTRA1 and breast cancer.